Publication date: Jun 21, 2026
By day 180, 8 participants in the metformin group and 18 in the placebo group reported receiving a clinician diagnosis. Symptoms were reported by 33 participants in the metformin group and 46 in the placebo group. They were randomized to immediate-release metformin or placebo for 14 days. Most participants reflected a contemporary outpatient population with prior immunity. Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial. Participants had confirmed SARS-CoV-2 infection and at least 2 COVID-19 symptoms within 7 days of symptom onset. The adjusted risk of post-acute sequelae of SARS-CoV-2 was 0. 8 percentage points lower with metformin, with a 95% credible interval of -2. 2 to 0. 6.
| Concepts | Keywords |
|---|---|
| Latino | Clinician |
| Month | Cov |
| Outpatient | Covid |
| Signalmetformin | Diagnosed |
| Efficacy | |
| Infection | |
| Long | |
| Metformin | |
| Participants | |
| Placebo | |
| Randomized | |
| Reported | |
| Risk | |
| Sars | |
| Symptoms |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Infectious Diseases |
| disease | MESH | hypoglycemia |
| disease | MESH | lactic acidosis |
| pathway | REACTOME | Release |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | infection |
| disease | MESH | COVID-19 |
| disease | MESH | Long COVID |
| drug | DRUGBANK | Metformin |